EIPG Newsletter

Biosimilars to provide better access at sustainable costs

In the era of the personalisation of therapies, a better access to cure closely relates to the ability to sustain the very high costs of medicines that are far more sophisticaded than just some twenty years ago.

Germany: The Rx-mail order German affair

The sentence of the European Court of Justice of Oct. 2016 leaves still open in Germany the debate on how to handle the possibility to order Rx medicines online on foreing sites. Learn about the open issues and the possible solutions...

Many new clinical guidelines from EMA

Compliance of the trial master file and arrangements for the good clinical practice inspection procedures are discussed by new guidelines recently released by the European medicines Agency. Learn about the new requirements...

The dispute on CRISPR-Cas9 patents is still open

The Broad Institute is the winner of the first round of judgement on CRISPR-Cas9 patents. But the battle is far to be at the end, and new legal actions are expected by the University of California’s leaded group. Learn more about the current status of a dispute that could change the future of medicine...

The 2017 European Semester Country Reports

The 2017 European Semester Country reports published by the European Commission indicates the need to complete the reform of healthcare systems to progress towards cost-effectiveness and access to services. Many different measures are mentioned, according to the actual situation of the various countries...